 Aduro Biotech, Inc. ADRO, a clinical-stage biopharmaceutical company focused on developing therapies targeting the immune system cGAS-STING and APRIL pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced a restructuring plan to further extend the companys operating capital and align personnel towards executing its clinical development strategy. Following a detailed review of its operations and growth opportunities, Aduro intends to reduce its current workforce by 51 employees approximately 59 percent across the organization, minimize its corporate facilities footprint and shut down the Aduro Biotech Europe headquarters in Oss, The Netherlands by the end of the third quarter of 2020. The reduction in ongoing operating expenses is expected to extend the Companys cash runway. 